Biological implications and clinical potential of invasion and migration related miRNAs in glioma

Xin Guo, Hengxing Jiao, Lele Cao, Facai MengFrontiers in Integrative Neuroscience 2022 · DOI

Abstract

Gliomas are the most common primary malignant brain tumors and are highly aggressive. Invasion and migration are the main causes of poor prognosis and treatment resistance in gliomas. As migration and invasion occur, patient survival and prognosis decline dramatically. MicroRNAs (miRNAs) are small, non-coding 21-23 nucleotides involved in regulating the malignant phenotype of gliomas, including migration and invasion. Numerous studies have demonstrated the mechanism and function of some miRNAs in glioma migration and invasion. However, the biological and clinical significance (including diagnosis, prognosis, and targeted therapy) of glioma migration and invasion-related miRNAs have not been systematically discussed. This paper reviews the progress of miRNAs-mediated migration and invasion studies in glioma and discusses the clinical value of migration and invasion-related miRNAs as potential biomarkers or targeted therapies for glioma. In addition, these findings are expected to translate into future directions and challenges for clinical applications. Although many biomarkers and their biological roles in glioma invasion and migration have been identified, none have been specific so far, and further exploration of clinical treatment is still in progress; therefore, we aimed to further identify specific markers that may guide clinical treatment and improve the quality of patient survival.

Introduction

Gliomas represent the most prevalent and aggressive primary malignant brain tumors. Their defining characteristic is "fatal aggressiveness"—the relentless ability of cancer cells to migrate and invade healthy brain tissue. This invasive nature makes complete surgical resection nearly impossible, leading to high recurrence rates and poor patient outcomes. While the role of microRNAs (miRNAs)—short, non-coding RNA sequences that regulate gene expression—is increasingly recognized, a systematic clinical overview has been lacking. This paper bridges the gap between molecular biology and clinical application, organizing research into a roadmap for future glioma diagnosis and treatment.

Methods and Framework

This comprehensive review synthesizes findings from the last decade, categorizing the role of miRNAs across four critical cellular dimensions that drive glioma progression:

  1. Epithelial-to-Mesenchymal Transition (EMT): The process by which cells gain mobility.
  2. Hypoxia: Adaptation to low-oxygen environments within the tumor.
  3. Angiogenesis: The induction of new blood vessel growth to sustain the tumor.
  4. Tumor Microenvironment (TME): The recruitment of surrounding cells, such as macrophages and fibroblasts, to facilitate spread.
Overview of miRNA involvement in key cellular processes driving glioma invasion and migration.

The study utilizes data synthesized from major genomic repositories, including The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), and the Gene Expression Omnibus (GEO), to correlate miRNA expression patterns with clinical outcomes.

Key Insights: Molecular Puppet Masters

The review highlights several sophisticated mechanisms through which miRNAs exert control:

  • The "Sponge" Effect: The lncRNA/miRNA/mRNA axis reveals that long non-coding RNAs (lncRNAs) can act as "sponges," soaking up miRNAs and preventing them from binding to their target mRNAs. This regulatory layer means the absence of a miRNA can be as impactful as its presence.
  • Pathway Regulation: miRNAs often regulate entire signaling pathways rather than single genes. For instance, miR-25 promotes migration by simultaneously repressing inhibitors like FBXW7 and DKK3, effectively accelerating the cell cycle while removing its natural brakes.
  • Exosomal Communication: Tumors secrete exosomal miRNAs into the blood and cerebrospinal fluid (CSF). Protected by lipid membranes, these stable molecules are ideal candidates for non-invasive "liquid biopsies."
  • TME Reprogramming: miRNAs are secreted to "reprogram" the environment, turning normal macrophages into Tumor-Associated Macrophages (TAMs) that assist tumor growth and immune evasion.

Key Results and Clinical Potential

The review provides a detailed summary of miRNAs and their specific clinical implications, serving as a reference for diagnostic and prognostic markers.

Summary of specific miRNAs, their target pathways, and clinical implications in glioma.

Key findings include:

  • Diagnostic Markers: miR-210 and miR-182 are strong candidates for early serum-based detection.
  • Prognostic Indicators: Low expression levels of miR-497 or miR-135a-5p are quantitatively linked to significantly shorter survival times.
  • Therapeutic Delivery: Advances in nanocarriers, such as PEG-coated liposomes and DNA nanomachines, are being developed to protect miRNA molecules and help them cross the blood-brain barrier (BBB).

Limitations and Future Directions

Despite significant progress, several challenges remain:

  • Specificity: Many miRNAs are associated with multiple cancers; identifying a "glioma-specific" signature is a priority.
  • The Delivery Problem: The BBB remains a major obstacle. While nanoparticles are promising, achieving therapeutic concentrations without systemic toxicity is still experimental.
  • Standardization: Clinical application requires uniform protocols for measuring miRNA to ensure consistency across studies.
  • Combination Therapy: The next frontier involves using miRNA-based drugs alongside traditional chemotherapies, like Temozolomide, to overcome treatment resistance.

Summary updated

Abstract

Gliomas are the most common primary malignant brain tumors and are highly aggressive. Invasion and migration are the main causes of poor prognosis and treatment resistance in gliomas. As migration and invasion occur, patient survival and prognosis decline dramatically. MicroRNAs (miRNAs) are small, non-coding 21-23 nucleotides involved in regulating the malignant phenotype of gliomas, including migration and invasion. Numerous studies have demonstrated the mechanism and function of some miRNAs in glioma migration and invasion. However, the biological and clinical significance (including diagnosis, prognosis, and targeted therapy) of glioma migration and invasion-related miRNAs have not been systematically discussed. This paper reviews the progress of miRNAs-mediated migration and invasion studies in glioma and discusses the clinical value of migration and invasion-related miRNAs as potential biomarkers or targeted therapies for glioma. In addition, these findings are expected to translate into future directions and challenges for clinical applications. Although many biomarkers and their biological roles in glioma invasion and migration have been identified, none have been specific so far, and further exploration of clinical treatment is still in progress; therefore, we aimed to further identify specific markers that may guide clinical treatment and improve the quality of patient survival.
BibTeX
@inproceedings{guo2022biological,
  author = {Xin Guo and Hengxing Jiao and Lele Cao and Facai Meng},
  title = {{Biological implications and clinical potential of invasion and migration related miRNAs in glioma}},
  booktitle = {Frontiers in Integrative Neuroscience},
  year = {2022},
  doi = {10.3389/fnint.2022.989029},
}
Figure